<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301599</url>
  </required_header>
  <id_info>
    <org_study_id>2009-09-024</org_study_id>
    <nct_id>NCT01301599</nct_id>
  </id_info>
  <brief_title>Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the comparison between alpha blocker monotherapy and
      5-alpha-reductase inhibitor monotherapy following combination therapy in benign prostatic
      hyperplasia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric change of IPS and Numeric change of IPSS total score</measure>
    <time_frame>from baseline to 12 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in patients' symptom questionnaires : IPSS, ICIQ male LUTS</measure>
    <time_frame>from baseline to 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urodynamic parameters : maximal flow rate and PVR</measure>
    <time_frame>from baseline to 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in finding of TRUS</measure>
    <time_frame>from baseline to 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Change and percent change in PSA</measure>
    <time_frame>from baseline to 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety evaluation : incidence and severity of adverse events</measure>
    <time_frame>12 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">315</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>combination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination therapy of alpha blocker and 5-alpha-reductase inhibitor medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alpha blocker group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>alpha blocker monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 ARI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 alpha-reductase inhibitor group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination therapy</intervention_name>
    <description>alpha blocker and 5-alpha-reductase inhibitor medication</description>
    <arm_group_label>combination group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha blocker monotherapy</intervention_name>
    <description>alpha blocker monotherapy group</description>
    <arm_group_label>alpha blocker group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 alpha reductase inhibitor monotherapy</intervention_name>
    <description>5 alpha reductase inhibitor monotherapy</description>
    <arm_group_label>5 ARI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male aged 45 years old and above (with no upper limit of age)

          2. patients who underwent combination therapy of alpha blocker and 5 ARI for more than 9
             months

          3. IPSS â‰¤ 12

          4. Ability and willingness to correctly complete the micturition diary and questionnaire

          5. Capable of understanding and having signed the informed consent form after full
             discussion of the research nature of the treatment and its risks and benefits

        Exclusion Criteria:

          1. An anticholinergic or antidiuretic if started less than 3 months prior to screening

          2. Patients who had surgical treatment due to LUTS

          3. Patients with suspected neurogenic bladder disorder

          4. Patients with cancer of any type including cancer of the prostate or bladder

          5. Patients with urethral stricture or bladder neck contracture

          6. Patients with suspicious chronic prostatitis/chronic pelvic pain syndrome

          7. Acute bacterial prostatitis less than 6 months prior to screening

          8. Symptomatic acute urinary tract infection (UTI) less than 1 months prior to screening

          9. Patients who had underwent prostatic biopsy less than one month prior to screening

         10. Patients who had unstable angina or cerebral vascular disease less than 6 months prior
             to screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Sung Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyu-Sung Lee, Ph.D</last_name>
    <phone>82-2-3410-3554</phone>
    <email>ksleedr@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu-Sung Lee, Ph.D</last_name>
      <phone>82-2-3410-3554</phone>
      <email>ksleedr@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>alpha blocker</keyword>
  <keyword>5-alpha reductase inhibitor</keyword>
  <keyword>combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
    <mesh_term>5-alpha Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

